Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

Sponsor
AstraZeneca
Study ID
NCT06231693
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trastuzumab deruxtecan — DRUG
    Patients with RE\<10% and HER2-Low breast cancer that have received Trastuzumab-deruxtecan in the metastatic setting

Study Details

A national, multicenter, retrospective, observational study (Real-World Evidence-RWE) aimed to assess the efficacy of Trastuzumab-deruxtecan (T-DXd) in patients with triple-negative (RE\<10%) metastatic HER2-Low breast cancer.

Key Dates

Start date
Dec 4, 2023
Status verified
Apr 2025
Primary completion
Mar 26, 2024
Completion
Mar 26, 2024

Study Design

Enrollment
2 participants (actual)

Arms

  • Arm: Trastuzumab-deruxtecan

Primary Outcome Measure

Time to Next Treatment [ Time Frame: Through study completion, an average of 1 year ]

Related Studies